Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share News

TOP NEWS: AstraZeneca's cancer drug Lynparza approved by NHS England

6th Apr 2023 07:55

(Alliance News) - The NHS has approved the use of a drug by AstraZeneca PLC which could benefit hundreds of patients with breast cancer and prostate cancer. Read More

LONDON MARKET CLOSE: Risk-off mood prevails but FTSE 100 outperforms

5th Apr 2023 17:01

(Alliance News) - Stocks in London closed largely lower on Wednesday, while the FTSE 100 ended in the green thanks to a solid performance from utility and pharmaceutical stocks. Read More

AstraZeneca receives positive interim trial results for Imfinzi drug

5th Apr 2023 09:13

(Alliance News) - AstraZeneca PLC on Wednesday said it has received positive results from interim analysis of the DUO-O phase 3 trial of its Imfinzi drug. Read More

TOP NEWS: AstraZeneca's ultomiris recommended for EU approval

3rd Apr 2023 08:45

(Alliance News) - AstraZeneca PLC on Monday said the EU's Committee for Medicinal Products for Human Use of the European Medicine Agency recommended the approval of ultomiris for the treatment of adult patients with a form of neuromyelitis optica spectrum disorder. Read More

AstraZeneca signs exclusive global license deal with KYM Biosciences

30th Mar 2023 09:27

(Alliance News) - AstraZeneca PLC on Thursday said it has completed an exclusive global license agreement with KYM Biosciences Inc for its CMG901 treatment. Read More

LONDON BRIEFING: Stocks add to rebound; SSE ups earnings guidance

30th Mar 2023 07:57

(Alliance News) - Stocks in London are set to build on Wednesday's gains, as risk appetite recovers following the recent banking turmoil. Read More

TOP NEWS: AstraZeneca hails eplontersen; Enhertu wins another approval

27th Mar 2023 08:52

(Alliance News) - AstraZeneca PLC on Monday announced positive high-level results from its Neuro-TTRansform phase III trial for eplontersen, while Enhertu received another approval in Japan. Read More

LONDON BRIEFING: Stocks called higher as banking crisis fears ease

27th Mar 2023 07:54

(Alliance News) - Stocks in London were called to open higher on Monday, as investors look past the recent turbulence in the banking sector. Read More

TOP NEWS: AstraZeneca's Calquence receives first approval in China

23rd Mar 2023 08:58

(Alliance News) - AstraZeneca PLC on Thursday said its drug Calquence received its first approval in China, for adults with previously treated mantle cell lymphoma, a rare type of non-Hodgkin lymphoma. Read More

UK dividends calendar - next 7 days

20th Mar 2023 15:50

Read More

LONDON BROKER RATINGS: Jefferies rates Future at 'hold'; Spirent upped

15th Mar 2023 09:36

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday: Read More

AstraZeneca hails trial results of cancer drugs Imfinzi and Tagrisso

9th Mar 2023 10:34

(Alliance News) - AstraZeneca PLC on Thursday hailed phase 3 trial results on its lung cancer drugs Imfinzi and Tagrisso. Read More

TOP NEWS: AstraZeneca hails Enhertu phase 2 trial results

6th Mar 2023 08:29

(Alliance News) - AstraZeneca PLC on Monday hailed phase 2 trial results of its cancer drug Enhertu, which it develops with Daiichi Sankyo Co Ltd. Read More

LONDON BRIEFING: Stocks called flat; AstraZeneca positive test results

6th Mar 2023 07:51

(Alliance News) - Stocks in London were called to open flat on Monday, as the dollar softened ahead of a consequential week for US economic data and monetary policy guidance. Read More

US FDA to discuss AstraZeneca and Merck's Lynparza cancer drug combo

2nd Mar 2023 17:20

(Alliance News) - AstraZeneca PLC and Merck & Co Inc said on Thursday that the US Food & Drug Administration will convene a meeting of the Oncologic Drugs Advisory Committee to discuss the supplemental new drug application for Lynparza in combination with abiraterone and prednisone or prednisolone. Read More

IN BRIEF: AstraZeneca prices three tranche global bond offering

1st Mar 2023 19:38

AstraZeneca PLC - Cambridge, UK-based pharmaceuticals firm - Announces wholly owned subsidiary AstraZeneca Finance prices a three tranche global bond offering totalling USD2.25 billion on February 28. Expects offering to close on March 3. Says the notes issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by AstraZeneca are USD1.1 billion of fixed rate notes with a coupon of 4.875%, maturing March 3 2028, USD650 million of fixed rate notes with a coupon of 4.900%, maturing March 3 2030, and USD500 million of fixed rate notes with a coupon of 4.875%, maturing March 3, 2033. Expects to use the net proceeds of the offering for general corporate purposes, which may include the refinancing of existing indebtedness. Read More

TOP NEWS: AstraZeneca closes CinCor buy; Enhertu wins Chinese approval

24th Feb 2023 14:35

(Alliance News) - AstraZeneca PLC on Friday reported that it completed the acquisition of CinCor Pharma Inc, which focuses on hypertension and chronic kidney disease, while its cancer drug Enhertu won another approval, its first in China. Read More

LONDON MARKET CLOSE: FTSE 100 struggles, but European peers rise

23rd Feb 2023 17:00

(Alliance News) - Stock prices in London closed mixed on Thursday, with blue-chips ending in the red on renewed concerns of higher rates in the US, as well as a host of stocks going ex-dividend. Read More

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

23rd Feb 2023 09:02

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings. Read More

AstraZeneca signs USD63 million agreement to address gastric cancer

23rd Feb 2023 09:01

(Alliance News) - AstraZeneca PLC on Thursday said it has signed an exclusive licence agreement alongside KYM Biosciences Inc for CMG901, an antibody drug conjugate looking to address gastric cancer. Read More

FTSE 100 Latest
Value10,126.78
Change-68.57